• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NanoString Technologies Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Financial Statements and Exhibits

    2/13/24 5:24:14 PM ET
    $NSTG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NSTG alert in real time by email
    nstg-20240213
    false000140170800014017082024-02-132024-02-13

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
     _______________________________ 
    FORM 8-K
    __________________________
     CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): February 13, 2024  
    _______________________________ 
    NanoString Technologies, Inc.
    (Exact name of registrant as specified in its charter)
      ________________________________
    Delaware001-3598020-0094687
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)

    530 Fairview Avenue North
    Seattle, Washington 98109
    (Address of principal executive offices, including zip code)

    (206) 378-6266
    (Registrant’s telephone number, including area code)

    (Former name or former address, if changed since last report)
      ____________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.0001 par value per shareNSTGThe NASDAQ Stock Market LLC
    (The NASDAQ Global Market)
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging Growth Company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act).   ¨

    Item 1.03. Bankruptcy or Receivership.
    As previously disclosed, on February 4, 2024, NanoString Technologies, Inc. (the “Company”) and certain of its subsidiaries (together, the “Debtors”) filed voluntary petitions under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (such court, the “Court” and such cases, the “Cases”).
    On February 13, 2024, a notice (the “Notice of Commencement”) of the commencement of the Cases was served on certain notice parties. Additional information about the Cases can be found at https://cases.ra.kroll.com/nanostring/.
    The foregoing description of the Notice of Commencement does not purport to be complete and is qualified in its entirety by reference to the full text of the Notice of Commencement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.
    Cautionary Note Regarding Forward-Looking Statements
    This Form 8-K includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These forward-looking statements reflect the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and the development of the industry in which we operate may differ materially from the forward-looking statements contained herein. Any forward-looking statements that we make in this Form 8-K speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Form 8-K or to reflect the occurrence of unanticipated events. The Company’s forward-looking statements in this Form 8-K include, but are not limited to, statements about the Company’s plans to sell its assets pursuant to chapter 11 of the U.S. Bankruptcy Code; the Company’s intention to continue operations during the Cases; the Company’s belief that the 363 sale process will be in the best interest of the Company and its stakeholders; and other statements regarding the Company’s strategy and future operations, performance and prospects among others. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks associated with the potential adverse impact of the Cases on the Company’s liquidity and results of operations; unpredictability of trading markets and whether a market will be established for the Company’s common stock; changes in the Company’s ability to meet its financial obligations during the Cases and to maintain contracts that are critical to its operations; the outcome and timing of the Cases and any potential asset sale; the effect of the filing of the Cases and any potential asset sale on the Company’s relationships with vendors, regulatory authorities, employees and other third parties; possible proceedings that may be brought by third parties in connection with the Cases or the potential asset sale; uncertainty regarding obtaining Court approval of a sale of the Company’s assets or other conditions to the potential asset sale; and the timing or amount of any distributions, if any, to the Company’s stakeholders.
    Item 9.01 Financial Statements and Exhibits.
    (d) Exhibits.
    Exhibit No.Description
    10.1
    Notice of Chapter 11 Bankruptcy Case.
    104The cover page from NanoString Technologies, Inc.’s Current Report on Form 8-K is formatted in iXBRL.
    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    NanoString Technologies, Inc.
    Date:February 13, 2024By:/s/ R. Bradley Gray
     R. Bradley Gray
     President and Chief Executive Officer

    Get the next $NSTG alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NSTG

    DatePrice TargetRatingAnalyst
    11/27/2023Overweight → Neutral
    JP Morgan
    11/21/2023Outperform → Neutral
    Robert W. Baird
    7/5/2023$18.00Overweight
    JP Morgan
    2/2/2023$15.00Buy
    UBS
    3/24/2022$50.00Buy
    Canaccord Genuity
    3/2/2022$85.00 → $70.00Overweight
    JP Morgan
    More analyst ratings

    $NSTG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NanoString Announces Completion of Financing to Support Restructuring Process

      $47.5 Million in New Financing Secured from Existing Noteholders, Upsized from Initial $40 million Commitment Supports Mission to Continue Serving Life Sciences Researchers Worldwide NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the Company has entered into a credit agreement with its existing lenders comprised of (a) $12,500,000 in new money term loans which have already been approved for funding pursuant to the February 5 interim order of the U.S. Bankruptcy court approving the credit facility, and (b) an additional $35,000,000 in new money term loans to be funded upon entry of the final

      2/9/24 6:30:00 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Takes Steps to Restructure Its Business and Protect Its Mission to Map the Universe of Biology

      Initiates Voluntary Chapter 11 Restructuring Proceedings with Additional $40 Million in Financing Secured from Existing Noteholders to Facilitate Process Continuing to Serve Life Sciences Researchers Worldwide NanoString Technologies, Inc. (NASDAQ:NSTG) ("NanoString" or "the Company"), a leading provider of life science tools for discovery and translational research, today announced that steps are being taken to protect its business, customers, employees and its mission to "Map the Universe of Biology." With support from key creditors, NanoString and certain of its subsidiaries have voluntarily initiated a chapter 11 restructuring proceeding in the United States Bankruptcy Court for the

      2/4/24 7:45:00 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability

      Three customers will present inaugural studies powered by the novel CosMx Whole Transcriptome Panel during annual AGBT meeting NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the CosMx™ Human 6K Discovery Panel, the industry's first single-cell spatial panel enabling research scientists to measure over 6,000 RNA targets, representing nearly every human biological pathway. Building on this breakthrough product developed for the CosMx Spatial Molecular Imager (SMI), NanoString and independent researchers will also highlight recently achieved whole transcriptome imag

      2/1/24 6:00:00 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NanoString Technologies downgraded by JP Morgan

      JP Morgan downgraded NanoString Technologies from Overweight to Neutral

      11/27/23 7:30:05 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Technologies downgraded by Robert W. Baird

      Robert W. Baird downgraded NanoString Technologies from Outperform to Neutral

      11/21/23 7:36:01 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan resumed coverage on NanoString Technologies with a new price target

      JP Morgan resumed coverage of NanoString Technologies with a rating of Overweight and set a new price target of $18.00

      7/5/23 7:22:55 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Beechem Joseph M was granted 564 shares, increasing direct ownership by 0.60% to 95,017 units

      4 - NanoString Technologies Inc (0001401708) (Issuer)

      9/5/23 4:38:19 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Gray R Bradley was granted 287 shares, increasing direct ownership by 0.08% to 338,682 units

      4 - NanoString Technologies Inc (0001401708) (Issuer)

      9/5/23 4:36:22 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Garland Jonathan Todd

      4 - NanoString Technologies Inc (0001401708) (Issuer)

      8/28/23 4:26:32 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    SEC Filings

    See more
    • NanoString Technologies Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Financial Statements and Exhibits

      8-K - NanoString Technologies Inc (0001401708) (Filer)

      2/13/24 5:24:14 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - NanoString Technologies Inc (0001401708) (Filer)

      2/8/24 10:45:26 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Technologies Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

      8-K - NanoString Technologies Inc (0001401708) (Filer)

      2/5/24 6:01:37 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    Leadership Updates

    Live Leadership Updates

    See more
    • NanoString Appoints Todd Garland as Chief Commercial Officer

      NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for discovery and translational research, today announced that Todd Garland has been appointed Chief Commercial Officer, effective August 28, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230826560279/en/NanoString Appoints Todd Garland as Chief Commercial Officer (Photo: Business Wire) Mr. Garland is a senior executive with more than 25 years of experience in healthcare and life sciences technologies that serve customers in the discovery, translational and clinical markets. Most recently Mr. Garland served as Chief Commercial Officer at Cytek B

      8/28/23 5:53:00 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DermTech Appoints Two New Board Members

      DermTech, Inc. (NASDAQ:DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Kirk D. Malloy, Ph.D. and Mark C. Capone, M.S. to the Company's board of directors, effective July 18,2022. These appointments expand DermTech's board of directors to eight members. "We are excited to welcome Kirk and Mark as new independent directors," commented Matt Posard, DermTech's chairman. "They are both accomplished life science executives, with an established track record in building companies, business development, capital formation and strategic partnerships. Their perspectives in guiding high-growth co

      7/18/22 4:05:00 PM ET
      $DMTK
      $NSTG
      Medical Specialities
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • NanoString Appoints Dr. Teresa Foy to Board of Directors

      Dr. Rob Hershberg steps down from Board after seven years of service NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the appointment of Dr. Teresa (Teri) Foy to the Board of Directors, effective April 18, 2022. "I am honored to welcome Dr. Foy to the team. Teri is a leader in immuno-oncology and cellular therapy, with decades of experience in pharmaceutical research," said president and chief executive officer Brad Gray. "Immunology and oncology are two of the most important applications for spatial biology, and Teri brings a wealth of knowledge in the ways that life science tools are utilized

      4/18/22 4:00:00 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by NanoString Technologies Inc. (Amendment)

      SC 13G/A - NanoString Technologies Inc (0001401708) (Subject)

      2/14/24 5:16:00 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by NanoString Technologies Inc. (Amendment)

      SC 13G/A - NanoString Technologies Inc (0001401708) (Subject)

      2/14/24 5:01:20 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by NanoString Technologies Inc.

      SC 13G - NanoString Technologies Inc (0001401708) (Subject)

      2/14/24 4:49:47 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    Financials

    Live finance-specific insights

    See more
    • NanoString Technologies Releases Operating Results for Third Quarter of 2023

      Completed Exchange Transaction with Convertible Note Holders Representing 94% of Outstanding Principal – Record Q3 Revenue of $48.1 Million, 63% Year on Year Growth and Above Upper End of Q3 Guidance Range – NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended September 30, 2023. The Company also announced it had reached agreement with holders to exchange approximately $216 million, or 94%, principal amount of its Convertible Notes for new Senior Secured Notes due September 1, 2026 and common stock warrants. "The last few months have been extraordinar

      11/6/23 4:00:00 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Provides Preliminary Financial and Operational Highlights for Third Quarter of 2023

      - Record Q3 Revenue of Over $48 Million, 63% Year on Year Growth, Above Upper End of Q3 Guidance Range - - Implementing Reorganization of R&D and Manufacturing Operations to Improve Path to Profitability - NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for the third quarter ended September 30, 2023, as well as a reorganization designed to accelerate the Company's path to profitability. "Our teams delivered strong revenue results for the third quarter, with preliminary results exceeding consensus estimates and the high end of our guidance rang

      10/10/23 6:00:00 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Technologies Releases Operating Results for Second Quarter of 2023

      – Record Q2 Revenue of $44.2 Million, 37% Year on Year Growth and Above Upper End of Q2 Guidance Range – - Retained More than $35 Million in CosMx Instrument Order Backlog at the End of Q2 - NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the second quarter ended June 30, 2023. "Strong growth in our spatial biology business and continued durability in our nCounter business helped us generate record revenue during the second quarter," said Brad Gray, President and CEO of NanoString. "We expect to continue to benefit from substantial CosMx instrument order backlog through

      8/3/23 4:00:00 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care